Annual Report 2023

Total sales for the year reached a new high of MNOK 526.4, representing 7% growth over 2022. Operating profit (EBIT) ended at MNOK 131.4 with and EBIT margin of 25% compared to last year EBIT of MNOK 141.2 or 28.7%.

Medistim continues to strengthen its position within both cardiac and vascular segments. Sales revenue from the cardiac segment ended in 2023 at MNOK 365.6 (MNOK 346.5), a 5.5% growth. Sales revenue from the vascular segment ended at MNOK 81.3 (MNOK 69.5), a 16.9% growth.
You can find the ESEF version of the report provided below, or alternatively, click on the image to access the PDF version.


Access the report on Oslo Børs Website